Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 2/20 | 0.35 |
| ▸ | MMP2 | P08253 | 2/20 | 0.35 |
| ▸ | MMP3 | P08254 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | MMP8 | P22894 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12951695 | 1.00 | MMP1 (0.35) | MMP1MMP2MMP3CA1CA2 | |
| SCHEMBL11851600 | 0.84 | FDPS (0.39) | CA1CA2 | |
| SCHEMBL4495084 | 0.82 | LAP3 (0.33) | — | |
| SCHEMBL14818473 | 0.82 | LAP3 (0.33) | — | |
| SCHEMBL4476335 | 0.82 | LAP3 (0.33) | — | |
| SCHEMBL11316721 | 0.81 | FDPS (0.42) | CA1CA2 | |
| SCHEMBL7941316 | 0.81 | FDPS (0.42) | CA1CA2 | |
| SCHEMBL11315637 | 0.81 | FDPS (0.42) | CA1CA2 | |
| SCHEMBL3939885 | 0.80 | LMNA (0.31) | MMP1MMP2MMP3CA1CA2 | |
| SCHEMBL11460321 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120323025-A1 | METHOD OF PRODUCING BERAPROST | Lung LLC | 2012-12-20 | — | — | US | disclosed |
| WO-2012174407-A1 | METHOD OF PRODUCING BERAPROST | Lung LLC (US) | 2012-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120323025-A1 | METHOD OF PRODUCING BERAPROST | PTGIS, PTGIR, VIP | MMP1 2828/4885MMP2 1877/4885MMP3 879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.